Axolabs is a contract research, development and manufacturing organisation (CRDMO) focused on oligonucleotide and nucleic acid therapeutics. The company combines over two decades of expertise in discovery, preclinical science, development, analytics and cGMP manufacturing to support the progression of RNA and DNA-derived therapeutic modalities from lead identification through to clinical and commercial supply. Axolabs operates as part of the LGC Group, with facilities and capabilities designed to address complex therapeutic development challenges and provide tailored solutions to pharmaceutical and biotechnology clients globally.

Key products and services:

• Contract research services covering lead identification, bioinformatics-driven design and early optimisation for oligonucleotide and nucleic acid therapeutics.
  Axolabs
• Preclinical development, including safety, pharmacokinetics, biodistribution studies and synthesis process development.
  Axolabs
• Preclinical CDMO services spanning non-GMP to GMP manufacturing and synthesis scale-up for toxicology studies.
  Axolabs
• Clinical CDMO services providing GMP-compliant production of therapeutic oligonucleotides for phases I–III and initial commercial requirements.
  Axolabs
• Analytical and bioanalytical support, including advanced characterisation and quality control.
  LGC

Axolabs maintains a global footprint with sites in Germany, the United States and expanding facilities such as upcoming GMP hubs, enabling integrated support across the full development spectrum of oligonucleotide therapeutics. Through its scientific heritage, technical capabilities and association with the LGC Group, Axolabs provides comprehensive, regulated services that help clients advance innovative nucleic acid-based medicines efficiently and compliantly.